Cargando…

Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis

BACKGROUND: Astragali Radix (AR) is widely-used for improving liver fibrosis, but, the mechanism of action has not been systematically explained. This study aims to investigate the mechanism of AR intervention in liver fibrosis based on comprehensive metabolomics combined with network pharmacology a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Dan, Li, Ruisheng, Wei, Shizhang, Gao, Sijia, Xu, Zhuo, Liu, Honghong, Wang, Ruilin, Li, Haotian, Cai, Huadan, Wang, Jian, Zhao, Yanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712842/
https://www.ncbi.nlm.nih.gov/pubmed/31467589
http://dx.doi.org/10.1186/s13020-019-0251-z
_version_ 1783446764699779072
author Wang, Dan
Li, Ruisheng
Wei, Shizhang
Gao, Sijia
Xu, Zhuo
Liu, Honghong
Wang, Ruilin
Li, Haotian
Cai, Huadan
Wang, Jian
Zhao, Yanling
author_facet Wang, Dan
Li, Ruisheng
Wei, Shizhang
Gao, Sijia
Xu, Zhuo
Liu, Honghong
Wang, Ruilin
Li, Haotian
Cai, Huadan
Wang, Jian
Zhao, Yanling
author_sort Wang, Dan
collection PubMed
description BACKGROUND: Astragali Radix (AR) is widely-used for improving liver fibrosis, but, the mechanism of action has not been systematically explained. This study aims to investigate the mechanism of AR intervention in liver fibrosis based on comprehensive metabolomics combined with network pharmacology approach. MATERIALS AND METHODS: UPLC–Q-TOF/MS based metabolomics technique was used to explore the specific metabolites and possible pathways of AR affecting the pathological process of liver fibrosis. Network pharmacology analysis was introduced to explore the key targets of AR regarding the mechanisms on liver fibrosis. RESULTS: AR significantly reduced the levels of ALT, AST and AKP in serum, and improved pathological characteristics. Metabolomics analysis showed that the therapeutic effect of AR was mainly related to the regulation of nine metabolites, including sphingosine, 6-keto-prostaglandin F1a, LysoPC (O-18:0), 3-dehydrosphinganine, 5,6-epoxy-8,11,14-eicosatrienoic acid, leukotriene C4, taurochenodesoxycholic acid, LysoPC (18:1 (9Z)) and 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine. Pathway analysis indicated that the treatment of AR on liver fibrosis was related to arachidonic acid metabolism, ether lipid metabolism, sphingolipid metabolism, glycerophospholipid metabolism and primary bile acid biosynthesis. Validation of the key targets by network pharmacology analysis of potential metabolic markers showed that AR significantly down-regulated the expression of CYP1B1 and up-regulated the expression of CYP1A2 and PCYT1A. CONCLUSION: Metabolomics combined with network pharmacology was used for the first time to clarify that the treatment of AR on liver fibrosis, which is related to the regulation of arachidonic acid metabolism and ether lipid metabolism by modulating the expression of CYP1A2, CYP1B1 and PCYT1A. And the integrated approach can provide new strategies and ideas for the study of molecular mechanisms of traditional Chinese medicines in the treatment of liver fibrosis.
format Online
Article
Text
id pubmed-6712842
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67128422019-08-29 Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis Wang, Dan Li, Ruisheng Wei, Shizhang Gao, Sijia Xu, Zhuo Liu, Honghong Wang, Ruilin Li, Haotian Cai, Huadan Wang, Jian Zhao, Yanling Chin Med Research BACKGROUND: Astragali Radix (AR) is widely-used for improving liver fibrosis, but, the mechanism of action has not been systematically explained. This study aims to investigate the mechanism of AR intervention in liver fibrosis based on comprehensive metabolomics combined with network pharmacology approach. MATERIALS AND METHODS: UPLC–Q-TOF/MS based metabolomics technique was used to explore the specific metabolites and possible pathways of AR affecting the pathological process of liver fibrosis. Network pharmacology analysis was introduced to explore the key targets of AR regarding the mechanisms on liver fibrosis. RESULTS: AR significantly reduced the levels of ALT, AST and AKP in serum, and improved pathological characteristics. Metabolomics analysis showed that the therapeutic effect of AR was mainly related to the regulation of nine metabolites, including sphingosine, 6-keto-prostaglandin F1a, LysoPC (O-18:0), 3-dehydrosphinganine, 5,6-epoxy-8,11,14-eicosatrienoic acid, leukotriene C4, taurochenodesoxycholic acid, LysoPC (18:1 (9Z)) and 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine. Pathway analysis indicated that the treatment of AR on liver fibrosis was related to arachidonic acid metabolism, ether lipid metabolism, sphingolipid metabolism, glycerophospholipid metabolism and primary bile acid biosynthesis. Validation of the key targets by network pharmacology analysis of potential metabolic markers showed that AR significantly down-regulated the expression of CYP1B1 and up-regulated the expression of CYP1A2 and PCYT1A. CONCLUSION: Metabolomics combined with network pharmacology was used for the first time to clarify that the treatment of AR on liver fibrosis, which is related to the regulation of arachidonic acid metabolism and ether lipid metabolism by modulating the expression of CYP1A2, CYP1B1 and PCYT1A. And the integrated approach can provide new strategies and ideas for the study of molecular mechanisms of traditional Chinese medicines in the treatment of liver fibrosis. BioMed Central 2019-08-28 /pmc/articles/PMC6712842/ /pubmed/31467589 http://dx.doi.org/10.1186/s13020-019-0251-z Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wang, Dan
Li, Ruisheng
Wei, Shizhang
Gao, Sijia
Xu, Zhuo
Liu, Honghong
Wang, Ruilin
Li, Haotian
Cai, Huadan
Wang, Jian
Zhao, Yanling
Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis
title Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis
title_full Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis
title_fullStr Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis
title_full_unstemmed Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis
title_short Metabolomics combined with network pharmacology exploration reveals the modulatory properties of Astragali Radix extract in the treatment of liver fibrosis
title_sort metabolomics combined with network pharmacology exploration reveals the modulatory properties of astragali radix extract in the treatment of liver fibrosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712842/
https://www.ncbi.nlm.nih.gov/pubmed/31467589
http://dx.doi.org/10.1186/s13020-019-0251-z
work_keys_str_mv AT wangdan metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT liruisheng metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT weishizhang metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT gaosijia metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT xuzhuo metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT liuhonghong metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT wangruilin metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT lihaotian metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT caihuadan metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT wangjian metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis
AT zhaoyanling metabolomicscombinedwithnetworkpharmacologyexplorationrevealsthemodulatorypropertiesofastragaliradixextractinthetreatmentofliverfibrosis